All In Biotech

Drug Trial Radar · NCT02636699

Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy

A Double-blind, Placebo-controlled, Randomized Phase 3 Pivotal Trial to Assess the Efficacy and Safety of Peanut Epicutaneous Immunotherapy With Viaskin Peanut in Peanut-allergic Children

Last checked: Nov 19, 2026Latest source record: Jun 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Title says "pivotal". Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

500

Actual

Start

Dec 2015

Primary completion

Aug 18, 2017

Study completion Aug 18, 2017

Sponsor

Lead sponsor
DBV TechnologiesIndustry
Sponsor type
Industry
First posted
Dec 22, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 4 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The PEPITES study evaluates the efficacy and safety of Viaskin Peanut 250 µg peanut protein to induce desensitization to peanut in peanut-allergic children 4 through 11 years of age after a 12-month treatment by epicutaneous immunotherapy (EPIT).

Conditions

  • Peanut Allergy

Interventions

  • Viaskin Peanut 250mcgBiological

    Peanut extract cutaneous patch

  • PlaceboBiological

    Cutaneous patch containing an inactive deposit manufactured to mimic peanut extract

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in Percentages of Treatment Responders at Month 12; Analyzed in the Overall PopulationTime frame: At Month 12

Locations

31 sites in 5 countries. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • University of California, Rady Children's Hospital

    San Diego, California

  • Stanford University School of Medicine

    Stanford, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • National Jewish Health

    Denver, Colorado

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Boston Childrens' Hospital

    Boston, Massachusetts

  • Jaffe Food Allergy Institute

    New York, New York

  • The University of North Carolina - Chapell Hill

    Chapel Hill, North Carolina

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • Children's Medical Center of Dallas

    Dallas, Texas

  • Baylor College of Medicine - Texas Children's Hospital

    Houston, Texas

  • ASTHMA, Inc.

    Seattle, Washington

  • Allergy Medical

    Brisbane, Australia

  • Princess Margaret Hospital for Children

    Perth, Australia

  • Children's Hospital Westmead

    Sydney, Australia

  • Centre de Recherche Appliquée en Allergie de Québec (CRAAQ)

    Québec, Canada

  • British Columbia Children's Hospital

    Vancouver, British Columbia, Canada

  • Cheema Research Inc.

    Mississauga, Ontario, Canada

  • Ottawa Allergy Asthma Research Institute

    Ottawa, Ontario, Canada

  • Gordon Sussman Clinical Research Inc.

    Toronto, Ontario, Canada

  • CHUM & CHU Sainte-Justine

    Montreal, Quebec, Canada

  • Charité Universitätsmedizin Berlin

    Berlin, Germany

  • St.-Marien-Hospital

    Bonn, Germany

  • Universitätsklinikum Erlangen

    Erlangen, Germany

  • Clinical Investigations Unit

    Cork, Ireland

  • Our Lady's Children's Hospital

    Dublin, Ireland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.